BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. 1999

V R Panday, and W W ten Bokkel Huinink, and J B Vermorken, and H Rosing, and F J Koopman, and M Swart, and J H Schellens, and J H Beijnen
Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam, CX, 1066, The Netherlands.

OBJECTIVE To investigate the pharmacokinetics of paclitaxel (Paxene) administered to patients with advanced breast or ovarian cancer and to document safety and anti-tumour activity in this study population. METHODS Patients with advanced breast or ovarian cancer were accrued to two clinical studies. Paclitaxel (Paxene) was administered as a 3-h 175 mg m-2 or as a 96-h 140 mg m-2(105 mg m-2 in the presence of liver metastases) infusion. Patients not responding to the 3-h schedule were permitted to cross-over to the 96-h schedule. The data were compared to those of five patients who were previously treated with paclitaxel administered as Taxol (140 mg m-296-h infusion) at our Institute. RESULTS Fourteen patients with breast cancer and five ovarian cancer patients were entered into this study. Seven patients received the 3-h regimen, and 12 were assigned to the 96-h schedule. Five patients originally treated with the 3-h schedule, crossed over to the 96-h arm. For the 3-h 175 mg m-2 dose, the area under the plasma concentration vs time curve (AUC) was (mean+/-SD) 16.9+/-4.8 h x micromol x l-1, whereas the AUCs were 5.5+/-1.2 and 4.3+/-0.9 h x micromol x l-1 for the 96-h 140 mg m-2 and 105 mg m-2 doses, respectively. The clearance of paclitaxel was independent of the dose in the 96-h group, indicating linear pharmacokinetics. Pharmacokinetics of Paxene (96-h 140 mg m-2) were not significantly different from the kinetics after Taxol (96-h 140 mg m-2) administration.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

V R Panday, and W W ten Bokkel Huinink, and J B Vermorken, and H Rosing, and F J Koopman, and M Swart, and J H Schellens, and J H Beijnen
Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics.
December 1997, Seminars in oncology,
V R Panday, and W W ten Bokkel Huinink, and J B Vermorken, and H Rosing, and F J Koopman, and M Swart, and J H Schellens, and J H Beijnen
Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
June 1995, Clinical cancer research : an official journal of the American Association for Cancer Research,
V R Panday, and W W ten Bokkel Huinink, and J B Vermorken, and H Rosing, and F J Koopman, and M Swart, and J H Schellens, and J H Beijnen
Safety and cost-effectiveness of paclitaxel administered as a 1-hour infusion versus a 3-hour infusion for various malignancies.
January 2004, Journal of infusion nursing : the official publication of the Infusion Nurses Society,
V R Panday, and W W ten Bokkel Huinink, and J B Vermorken, and H Rosing, and F J Koopman, and M Swart, and J H Schellens, and J H Beijnen
Single-agent paclitaxel as a 3-hour infusion.
December 1996, Seminars in oncology,
V R Panday, and W W ten Bokkel Huinink, and J B Vermorken, and H Rosing, and F J Koopman, and M Swart, and J H Schellens, and J H Beijnen
Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease.
June 1995, Seminars in oncology,
V R Panday, and W W ten Bokkel Huinink, and J B Vermorken, and H Rosing, and F J Koopman, and M Swart, and J H Schellens, and J H Beijnen
Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.
January 1996, The Journal of infusional chemotherapy,
V R Panday, and W W ten Bokkel Huinink, and J B Vermorken, and H Rosing, and F J Koopman, and M Swart, and J H Schellens, and J H Beijnen
Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.
January 1980, Cancer chemotherapy and pharmacology,
V R Panday, and W W ten Bokkel Huinink, and J B Vermorken, and H Rosing, and F J Koopman, and M Swart, and J H Schellens, and J H Beijnen
No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.
February 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
V R Panday, and W W ten Bokkel Huinink, and J B Vermorken, and H Rosing, and F J Koopman, and M Swart, and J H Schellens, and J H Beijnen
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.
May 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
V R Panday, and W W ten Bokkel Huinink, and J B Vermorken, and H Rosing, and F J Koopman, and M Swart, and J H Schellens, and J H Beijnen
Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial.
December 2002, Onkologie,
Copied contents to your clipboard!